Citations

Clear

3030 citation(s) found for "Susan, M".

Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Ellenberg, Susan S. , Krowka, Michael J. , Goldberg, David S. , Vargas, Hugo E. , Koch, David , Sharkoski, Tiffany, Al‐Naamani, Nadine , Fox, Alyson N. , Levitsky, Joshua, Oh, Jae K. , Lin, Grace , Song, Nianfu, Mottram, Carl, Doyle, Margaret F. , Gupta, Samir , Fallon, Michael B. , Vargas, Hugo, Vargas, Hugo E , Al-Naamani, Nadine , Kawut, Steven M. , Brown, Robert S. , Song, Nianfu, Kaplan, David E. , Koch, David

Mayo Clinic

Liver Transplantation | February 28, 2019 | Volume: 25 | Issue: 8 | Pages: 1155-1164

10.1002/lt.25438 | PMID 30816637 Get It

The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar‐arterial oxygen gradient (AaPO2) at 3 months in patients with HPS. We performed a randomized, double‐blind, placebo‐controlled parallel trial of sorafenib in patients with HPS at 7 centers. A total of 28 patients with HPS were randomized to sorafenib 400 mg by mouth daily or a matching placebo in a 1:1 ratio. We found no statistically significant difference in the median change in AaPO2 from baseline to 12 weeks between the patients allocated to sorafenib (4.5 mm Hg; IQR, –3.8 to 7.0 mm Hg) and those allocated to placebo (–2.4 mm Hg; IQR, –4.8 to 8.2 mm Hg; P = 0.70). There was also no difference between the groups in terms of degree of intrapulmonary shunting by contrast echocardiography. Sorafenib significantly reduced circulating levels of angiogenic markers, including vascular endothelial growth factor receptors (P < 0.01) and TIE2‐expressing M2 monocytes (P = 0.03), but it reduced the mental component scores of the Short Form 36 (P = 0.04), indicating a worse quality of life. In conclusion, sorafenib did not change the AaPO2 or other disease markers at 3 months in patients with HPS. Alternative antiangiogenic therapies or treatments targeting other pathways should be investigated.
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Treatment of Posaconazole-Induced Peripheral Neuropathy With Methylprednisolone and Magnesium Infusions: A Case Report
Hussain, Sadia, Nissen, Susan E., Holland, Steven M. , Sandroni, Paola , Lionakis, Michail S. , Nissen, Susan, Nissen, Susan

Mayo Clinic

Open Forum Infectious Diseases | February 23, 2019 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/ofid/ofz031 | PMID 31312664 Get It

Abstract The tolerability of long-term posaconazole use remains poorly defined. We present a patient who developed peripheral neuropathy following long-term exposure to the tablet formulation of posaconazole, which was treated with methylprednisolone and magnesium infusions. The potential role of methylprednisolone and magnesium infusions in managing this potentially irreversible triazole-associated complication requires further study.
Role of angiotensin-converting-enzyme inhibitors in stroke prevention
Fagan, Susan C., Lee, Linda A., Hess, David C.

Mayo Clinic

American Journal of Health-System Pharmacy | February 22, 2019 | Volume: 60 | Issue: 8 | Pages: 788-793

10.1093/ajhp/60.8.788 | PMID 12749165 Get It

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Mossé, Yaël P. , Fox, Elizabeth , Hall, David , Safgren, Stephanie L. , Carol, Hernán, Lock, Richard B. , Houghton, Peter J. , Smith, Malcolm A. , Barkauskas, Donald A. , Krailo, Mark , Voss, Stephan D. , Blaney, Susan M. , Weigel, Brenda J. , Teachey, David T. , Teachey, David T , Reid, Joel M. , Smith, Malcolm A , Berg, Stacey L , Safgren, Stephanie L , Berg, Stacey L.

Mayo Clinic

Clinical Cancer Research | February 18, 2019 | Volume: 25 | Issue: 11 | Pages: 3229-3238

10.1158/1078-0432.ccr-18-2675 | PMID 30777875 Get It

Abstract Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.
Medical Assessment and Triage of Pediatric Patients with Anorexia Nervosa in Primary Care
Homan, Kendra J. , Sim, Leslie , Crowley, Susan L. , Lebow, Jocelyn , Kransdorf, Lisa N. , Lebow, Jocelyn R, Kransdorf, Lisa N , Lebow, Jocelyn

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | February 12, 2019 | Volume: 40 | Issue: 2 | Pages: 92-98

10.1097/dbp.0000000000000629 | PMID 30747833 Get It

ABSTRACT: Objective: To examine the medical assessment and triage of pediatric patients with anorexia nervosa (AN) initially seen in primary care. Methods: A retrospective cohort study was conducted for all pediatric patients with AN who had eating/weight concerns and initially identified symptoms in primary care in a single health care system between January 1, 2010, and December 31, 2016. Information on presenting concern, medical assessment/laboratory tests, clinical diagnoses, treatment recommendations, and referrals were abstracted from the medical record. Results: Forty-one (mean age = 13.7 years; SD = 2.2) pediatric patients with AN had eating/weight concerns and initially identified symptoms in a primary care. Overall, only 5% (n = 2/41) of patients received an AN diagnosis during the index visit; a minority were assessed for electrolyte disturbance (n = 20), electrocardiogram abnormality (n = 18), hypothermia (n = 13), binge/purge behaviors (n = 13), orthostatic hypotension (n = 2), or dehydration (n = 1), and only 56% (n = 23) received triage consistent with practice recommendations. Although 61% (n = 25) met criteria for inpatient admission, inpatient hospitalization was recommended for only 2 patients. Patients who received triage consistent with practice recommendations received AN diagnosis and treatment significantly earlier than those who did not (p < 0.01 and p = 0.001, respectively). Conclusion: Findings suggest that pediatric patients with AN may not be receiving medical assessment and triage per practice recommendations in the primary care setting. Understanding barriers to evidence-based care for pediatric eating disorders may inform provider education and system-wide changes to enhance outcomes in these patients.
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy
Ludmir, Ethan B. , Mahajan, Anita , Jones, Jeremy , Ketonen, Leena , Su, Jack , Grosshans, David R. , McAleer, Mary Frances, McGovern, Susan L. , Lassen–Ramshad, Yasmin , Adesina, Adekunle M. , Dauser, Robert C., Weinberg, Jeffrey S. , Chintagumpala, Murali , Ludmir, Ethan B , Paulino, Arnold C. , McAleer, Mary Frances

Mayo Clinic

Neuro-Oncology | February 6, 2019 | Volume: 21 | Issue: 5 | Pages: 686-695

10.1093/neuonc/noz042 | PMID 30753704 Get It

Public perceptions of changing the terminology for low-risk thyroid cancer: a qualitative focus group study
Nickel, Brooke , Semsarian, C. , Moynihan, Ray , Barratt, Alexandra , Jordan, Susan J. , McLeod, Donald S.A. , Brito, Juan P. , McCaffery, Kirsten , Brito, Juan P

Mayo Clinic

BMJ Open | February 6, 2019 | Volume: 9 | Issue: 2 | Pages: e025820

10.1136/bmjopen-2018-025820 | PMID 30813118 Get It

Objectives To investigate public perceptions of overdiagnosis and overtreatment in low-risk thyroid cancer and explore opinions regarding the proposed strategy to change the terminology of low-risk cancers. Design Qualitative study using focus groups that included a guided group discussion and presentation explaining thyroid cancer, overdiagnosis and overtreatment, and proposed communication strategies. Transcripts were analysed thematically. Setting Sydney, Australia. Participants Forty-seven men and women of various ages from a range of socioeconomic backgrounds with no personal history of thyroid cancer. Results Participants had low pre-existing general awareness of concepts of overdiagnosis and overtreatment and expressed concern regarding this new information in relation to thyroid cancer. Overall, participants understood why the strategy to change the terminology was being proposed and could see potential benefits including reducing the negative psychological impact and stigma associated with the term ‘cancer’; however, many still had reservations about the strategy. The majority of the concerns were around their worry about the risk of further disease progression and that changing the terminology may create confusion and cause patients not to take the diagnosis and its associated managements seriously. Despite varied views towards the proposed strategy, there was a strong overarching desire for greater patient and public education around overdiagnosis and overtreatment in both thyroid cancer and cancer generally in order to complement any revised terminology and/or other mitigation strategies. Conclusions We found a strong and apparently widely held desire for more information surrounding the topic of overdiagnosis and overtreatment. Careful consideration of how to inform both the public and current patients about the implications of a change in terminology, including changes to patients’ follow-up or treatments, would be needed if such a change were to go ahead.
Abstract A36: Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution in Caucasian and African American women: The Susan G. Komen Tissue Bank
Horne, Hisani N., Xiang, Jackie , Brinton, Louise A. , Storniolo, Anna Maria , Gierach, Gretchen L. , Gierach, Gretchen L , Oh, Hannah , Pfeiffer, Ruth M. , Falk, Roni T. , Pollak, Michaël , Sherman, Mark E. , Figueroa, Jonine D.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 4, 2019 | Volume: 27 | Issue: 7_Supplement | Pages: A36-A36

10.1158/1538-7755.disp17-a36 Get It

Abstract Background: Insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 play important roles in carcinogenesis, particularly for breast cancer. However, little is known about whether the IGF system influences histologic characteristics of normal glandular tissue and whether relationships vary by race. Lesser degrees of age-related terminal duct lobular unit (TDLU) involution, as reflected by higher numbers of TDLUs and acini per TDLU, have been associated with higher breast cancer risk. We examined the associations of IGF measures with TDLU involution of normal breast using standardized TDLU measures. Methods: Among 715 Caucasian and 283 African American (AA) women with normal breast tissue samples from the Komen Tissue Bank, serum concentrations of IGF-I and IGFBP-3 were quantified using enzyme-linked immunosorbent assay (ELISA). Hematoxilyn and eosin-stained tissue sections were assessed for numbers of TDLUs (“TDLU count”) and acini/TDLU. Zero-inflated Poisson regression models with a robust variance estimator were used to estimate associations of IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio (tertiles) with TDLU count by race and menopausal status, adjusting for potential confounders. We also tested for interactions by race using likelihood ratio tests. Results: AA (vs. Caucasian) women had higher age-adjusted mean levels of serum IGF-I (137 vs. 131 ng/mL, p=0.07) and lower levels of IGFBP-3 (4165 vs. 4684 ng/mL, p&lt;0.0001); the differences persisted after adjustment for additional covariates including BMI and parity/age at first birth. Postmenopausal IGFBP-3 was inversely associated with TDLU count among both AA (RR T3vs.T1=0.49, 95% CI=0.28-0.84, p-trend=0.04) and Caucasian (RR T3vs.T1=0.63, 95% CI=0.41-0.99, p-trend=0.04) women. In premenopausal women, higher IGF-I:IGFBP-3 ratios were associated with higher TDLU count in Caucasians (OR T3vs.T1=1.33, 95% CI=1.01-1.31, p-trend=0.04) but not in AA (OR T3vs.T1=0.65, 95% CI=0.42-1.00, p-trend=0.05) women. There was no statistically significant interaction by race (p-interaction≥0.10). Conclusions: Our data suggest the potential role of the IGF system, particularly IGFBP-3, in TDLU involution of the normal breast among both Caucasian and AA women. Citation Format: Hannah OH, Ruth M. Pfeiffer, Roni T. Falk, Hisani N. Horne, Jackie Xiang, Michael Pollak, Louise A. Brinton, Anna Maria V. Storniolo, Mark E. Sherman, Gretchen L. Gierach, Jonine D. Figueroa. Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution in Caucasian and African American women: The Susan G. Komen Tissue Bank [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr A36.